Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8 + T cells

International Journal of Oncology

Volumn 40, Issue 3, 2012, Pages 764-772

  Xu, Xun ^a,b,c   Stockhammer, Florian ^b,d   Schmitt, Anita ^b,e   Casalegno Garduno, Rosaely ^b   Enders, Anne ^b   Mani, Jiju ^b,e   Classen, Carl Friedrich ^b   Linnebacher, Michael ^b   Freund, Mathias ^b   Schmitt, Michael ^b,e  

^a JIANGSU UNIVERSITY   (China)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c INSTITUTE OF MATERIALS RESEARCH   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Dendritic cells; Glioblastoma; T cells; Temozolomide

Indexed keywords

CD209 ANTIGEN; CD40 ANTIGEN; DENDRITIC CELL VACCINE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; TEMOZOLOMIDE; VIRUS ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL STRUCTURE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MALE; MIXED LYMPHOCYTE CULTURE; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL;

AGED; ANTIGENS, SURFACE; CD8-POSITIVE T-LYMPHOCYTES; DACARBAZINE; DENDRITIC CELLS; FEMALE; GLIOBLASTOMA; HUMANS; INTERLEUKIN-2; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; MONOCYTES; PHAGOCYTOSIS; PHENOTYPE;

EID: 84863115788     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1269     Document Type: Article

References (37)

1. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193, 2010.
2. Stummer W, Reulen HJ, Meinel T, et al: ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62: 564-576, 2008.
3. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
4. Agarwala SS and Kirkwood JM: Temozolomide. a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5: 144-151, 2000.
5. Ardon H, Van Gool S, Lopes IS, et al: Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 99: 261-272, 2010.
6. Ardon H, De Vleeschouwer S, Van Calenbergh F, et al: Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 54: 519-525, 2010.
7. Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S and De Vleeschouwer S: Dendritic cell therapy of high-grade gliomas. Brain Pathol 19: 694-712, 2009.
8. De Vleeschouwer S, Fieuws S, Rutkowski S, et al: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14: 3098-3104, 2008.
9. Liau LM, Prins RM, Kiertscher SM, et al: Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11: 5515-5525, 2005. (Pubitemid 41060828)
10. Pera MF, Köberle B and Masters JRW: Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. Br J Cancer 71: 904-905, 1995.
11. Li L, Schmitt A, Reinhardt P, et al: Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Cancer Immun 3: 8, 2003.
12. Li L, Reinhardt P, Schmitt A, et al: Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol Immunother 54: 685-693, 2005. (Pubitemid 40884165)
13. Li L, Giannopoulos K, Reinhardt P, et al: Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol 28: 855-861, 2006.
14. Schmitt A, Li L, Giannopoulos K, Greiner J, Reinhardt P, Wiesneth M and Schmitt M: Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Transfusion 48: 861-870, 2008. (Pubitemid 351614897)
15. + T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 106: 938-945, 2005.
16. Schmitt M, Schmitt A, Rojewski MT, et al: RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111: 1357-1365, 2008. (Pubitemid 351213422)
17. Schmitt M, Schmitt A, Reinhardt P, et al: Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 25: 841-848, 2004.
18. Shah MA and Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7: 2168-2181, 2001. (Pubitemid 32751613)
19. Liu G, Black KL and Yu JS: Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev Vaccines 5: 233-247, 2006. (Pubitemid 44183378)
20. Hatano M, Eguchi J, Tatsumi T, et al: EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 7: 717-722, 2005.
21. Schmitz M, Wehner R, Stevanovic S, et al: Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11. Cancer Lett 245: 331-336, 2007. (Pubitemid 44959365)
22. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL and Yu JS: HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64: 4980-4986, 2004. (Pubitemid 38924546)
23. Tang J, Flomenberg P, Harshyne L, Kenyon L and Andrews DW. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res 11: 5292-5299, 2005 (Pubitemid 41003718)
24. Yu JS, Wheeler CJ, Zeltzer PM, et al: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61: 842-847, 2001. (Pubitemid 32175145)
25. Kobayashi T, Yamanaka R, Homma J, Tsuchiya N, Yajima N, Yoshida S and Tanaka R: Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 52: 632-637, 2003. (Pubitemid 37268196)
26. Yamanaka R, Abe T, Yajima N, et al: Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89: 1172-1179, 2003. (Pubitemid 37363398)
27. Caruso DA, Orme LM, Neale AM, et al: Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 6: 236-246, 2004. (Pubitemid 39136507)
28. Yu JS, Liu G, Ying H, Yong WH, Black KL and Wheeler CJ: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64: 4973-4979, 2004. (Pubitemid 38924545)
29. Rutkowski S, De Vleeschouwer S, Kaempgen E, et al: Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91: 1656-1662, 2004. (Pubitemid 39546137)
30. Maes W and Van Gool SW: Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother 60: 153-160, 2011.
31. Yamanaka R, Homma J, Yajima N, et al: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11: 4160-4167, 2005. (Pubitemid 40791581)
32. Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM and Stone MJ: Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 7: 691-703, 2001. (Pubitemid 32707996)
33. Shurin MR, Yurkovetsky ZR, Tourkova IL, Balkir L and Shurin GV: Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int J Cancer 101: 61-68, 2002. (Pubitemid 34832998)
34. McGreal E, Miller J and Gordon S: Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr Opin Immunol 17: 18-24, 2005. (Pubitemid 40094008)
35. Stockhammer F, Misch M, Koch A, et al: Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol 100: 407-415, 2010.
36. Kurzen H, Schmitt S, Näher H and Möhler T: Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14: 515-522, 2003. (Pubitemid 37083156)
37. Chiba Y, Hashimoto N, Tsuboi A, et al: Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. Jpn J Clin Oncol 40: 395-403, 2010.